Characteristics | |
---|---|
Mean age at diagnosis (SD), y | 54.38 (11.57) |
Sex (%) | |
Male | 20 (43) |
Female | 27 (57) |
Performance status (%) | |
<2 | 36 (77) |
≥ 2 | 11 (23) |
Smoking history (%) | |
Current and former | 15 (32) |
Never | 32 (68) |
Charlson Comorbidity Index (%) | |
0 | 12 (25) |
1–2 | 25 (53) |
≥ 3 | 10 (21) |
Histology (%) | |
Adenocarcinoma | 46 (98) |
Adenosquamous carcinoma | 1 (2) |
Stage at diagnosis | |
IIIB | 7 (15) |
IV | 40 (85) |
Number of metastatic sites (%) | |
1–2 | 33 (70) |
≥ 3 | 14 (30) |
Metastatic site Brain (%) | |
No | 41 (87) |
Yes | 6 (15) |
Liver (%) | |
No | 45 (96) |
Yes | 2 (4) |
Lung (%) | |
No | 35 (74) |
Yes | 12 (26) |
Adrenal (%) | |
No | 43 (91) |
Yes | 4 (9) |
Soft tissue (%) | |
No | 45 (96) |
Yes | 2 (4) |
Bone (%) | |
No | 34 (72) |
Yes | 13 (28) |
Pleural (%) | |
No | 25 (53) |
Yes | 22 (47) |
Lymph node (%) | |
No | 13 (28) |
Yes | 34 (72) |
All lines therapy (%) | |
Chemotherapy | 19 (26) |
ROS1TKIs | 37 (51) |
Others | 16 (22) |
First-line therapy (%) | |
First-line ROS1 TKIs | 24 (51) |
Chemotherapy | 13 (28) |
Others | 10 (21) |
Ros-1 TKIs (%) | |
Ros-1 TKIs at first-line therapy | 24 (65) |
Ros-1 TKIs at any line therapy | 13 (35) |
Baseline laboratory values (Means, SD) | |
Leukocyte count | 8.26 (4.04) |
Neutrophil count | 5.98 (3.83) |
Hemoglobin | 135.67 (16.56) |
Platelet count | 281.78 (76.04) |
Carcinoembryonic antigen (CEA) | 15.34 (33.44) |
Lactate dehydrogenase (LDH) | 238.56 (109.37) |
C-reactive protein (CRP) | 13.67 (18.00) |
D-dimer | 3.97 (6.41) |